Document is current
Any future updates will be listed below
-
Authors
Chen, Zhixiang https://orcid.org/0009-0007-4526-1588
Dhruv, Harshil
Zhang, Xuqing
Rej, Rohan Kalyan https://orcid.org/0000-0003-0904-9137
Bai, Longchuan
McEachern, Donna
Kirchhoff, Paul
Nagilla, Rakesh
Jolivette, Larry J.
Rice, Cory T.
Orth, Peter https://orcid.org/0000-0002-8475-682X
Strickland, Corey O.
Priestley, E. Scott https://orcid.org/0000-0001-8390-1143
Mohammad, Helai P.
Wang, Meilin
Wen, Bo
Sun, Duxin https://orcid.org/0000-0002-6406-2126
Sui, Zhihua
Wang, Shaomeng https://orcid.org/0000-0002-8782-6950
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30CA046592)
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 24 March 2025
First Online: 1 May 2025
Competing interests
: The authors declare the following competing interest(s): The University of Michigan has filed a patent application on these IKZF2 degraders (patent publication No. WO2023183540, published on Sep. 28, 2023), which has been licensed to Oncopia Therapeutics, Inc and Proteovant Therapeutics, Inc. Z.C., R.R., L.B., X.Z., P.K. and S.W. are the co-inventors on this patent application. S.W. was a co-founder and served as a paid consultant to Oncopia Therapeutics, Inc. S.W. and the University of Michigan owned equity in Oncopia Therapeutics, Inc, which was acquired by Roivant Sciences, Inc and Proteovant Therapeutics, Inc. S.W. has been a paid consultant to Proteovant Therapeutics, Inc. and Roivant Sciences. The University of Michigan has received a research contract from Oncopia Therapeutics/ Proteovant Therapeutics, Inc for which S. Wang has served as the principal investigator. H.D., X.Z., R.N., L.J.J., C.T.R., P.O., C.O.S., E.S.P., H.P.M., Z.S. are current or former employees of Proteovant Therapeutics and/or SK Life Science Labs. All other authors declare no competing interest.
